One boy and two girls, were delivered by Dr. John Wideman with assistance from Dr. Taylor Massengill on Friday, Dec. 5.
KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
From pregnancy to sleepless nights, these best friends faced raising multiples in shared motherhood. They understand the ...